GEFITINIB (G-NIB) Tablet

$270.00

Gefitinib G-NIB Tablet represents a monumental therapeutic breakthrough in the management of EGFR-mutated non-small cell lung cancer, offering targeted therapy that can significantly improve outcomes and quality of life for patients facing this challenging condition. With careful monitoring, patient education, and access to treatment,

Tag:

GEFITINIB G-NIB

Description

Gefitinib G-NIB Tablet is a groundbreaking medication in the realm of oncology, offering a targeted treatment option for individuals grappling with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. With its active ingredient gefitinib, this oral medication represents a significant advancement in the management of this complex condition, providing renewed hope and significantly improved outcomes for patients facing this challenging diagnosis.

Key Features:

EGFR Tyrosine Kinase Inhibitor (TKI): Gefitinib is a selective inhibitor of the EGFR tyrosine kinase, a key signaling pathway involved in cell proliferation, survival, and angiogenesis. By blocking EGFR signaling, gefitinib effectively suppresses the growth and spread of cancer cells in NSCLC with activating EGFR mutations, including exon 19 deletions and exon 21 (L858R) substitutions.
Treatment of Non-Small Cell Lung Cancer (NSCLC): Gefitinib G-NIB Tablet is indicated for the first-line treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations. It represents a standard-of-care therapy for these patients, offering superior efficacy and tolerability compared to traditional chemotherapy.
Oral Administration: Administered orally once daily, Gefitinib G-NIB Tablet is typically taken on an empty stomach, at least one hour before or two hours after a meal. Patients should adhere strictly to the prescribed dosing schedule and follow healthcare provider instructions meticulously.
Efficacy: Clinical trials have demonstrated the remarkable efficacy of gefitinib in achieving objective response rates, progression-free survival, and overall survival benefits in patients with EGFR-mutated NSCLC. It has shown superiority over chemotherapy and other treatment modalities, both as a frontline therapy and in patients with acquired resistance to prior EGFR TKIs.
Multiple Strengths: Available in tablet form with standardized doses of gefitinib, Gefitinib G-NIB Tablet allows for personalized dosing tailored to individual patient needs and treatment responses, facilitating optimized therapeutic outcomes.
Side Effects: Common side effects of Gefitinib may include diarrhea, rash, acneiform eruptions, and interstitial lung disease. Patients should be closely monitored for adverse reactions, and dose adjustments or supportive care measures may be necessary to manage side effects.
Patient Education: Patients should receive comprehensive counseling on proper medication administration, potential side effects, and the importance of adherence to treatment. They should also be educated on the need for regular monitoring of liver function tests and other parameters to assess treatment response and detect any adverse effects.
Consultation with Healthcare Provider: Treatment with Gefitinib G-NIB Tablet should be initiated and monitored by a qualified oncologist experienced in the management of NSCLC. Close collaboration between the patient and healthcare provider is essential throughout the treatment journey.
Access and Affordability: Efforts should be made to ensure access to Gefitinib for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate the financial burden of treatment.

In conclusion, Gefitinib G-NIB Tablet represents a monumental therapeutic breakthrough in the management of EGFR-mutated non-small cell lung cancer, offering targeted therapy that can significantly improve outcomes and quality of life for patients facing this challenging condition. With careful monitoring, patient education, and access to treatment, Gefitinib holds promise in reshaping the landscape of lung cancer care and providing hope for those affected by this disease.